Critical issues in site-specific targeting of solid tumours: The carrier, the tumour barriers and the bioavailable drug

Expert Opinion on Drug Delivery

Volumn 5, Issue 2, 2008, Pages 205-219

  Hamad, Islam ^a   Moghimi, S Moein ^b  

^a UNIVERSITY OF BRIGHTON   (United Kingdom)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Cancer chemotherapy; Drug carriers; Hypersensitivity; Liposome; Multi drug resistance; Polymer drug conjugates; Polymeric nanoparticles

Indexed keywords

CAMPTOTHECIN; CARBOXYMETHYLDEXTRAN; CISPLATIN; CREMOPHOR; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOXORUBICIN; DRUG CARRIER; LIPOSOME; MACROGOL; N (2 HYDROXYPROPYL)METHACRYLAMIDE; PACLITAXEL; PACLITAXEL POLIGLUMEX; PROTECAN; STYRENE MALEIC ANHYDRIDE COPOLYMER; UNCLASSIFIED DRUG;

BREAST CANCER; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED RELEASE FORMULATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG TARGETING; HAND FOOT SYNDROME; HUMAN; LIVER TOXICITY; NEUTROPENIA; NONHUMAN; REVIEW; SINGLE DRUG DOSE; SOLID TUMOR;

ANTINEOPLASTIC AGENTS; BINDING SITES; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; DRUG CARRIERS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; POLYMERS;

EID: 39749124420     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.5.2.205     Document Type: Review

References (83)